Ashok Krishnamurthi
Managing Partner @ GreatPoint Ventures
San Francisco Bay Area, United States
Ashok Krishnamurthi is a Series A investor at GreatPoint Ventures in San Francisco Bay Area focused on Software and Health Care. Ashok Krishnamurthi Co-Founded Xsigo Systems, Inc., in 2004 and served as its Executive Chairman. Ashok served as the Chief Executive Officer of Xsigo Systems Inc. Mr. Krishnamurthi has over 28 years of experience in management and engineering. He joined Juniper Networks in 1995 and served as its Executive Vice President of Engineering sinceSeptember 2003. He served as Vice President and General Manager of Infrastructure Product Line of Juniper Networks Inc. He served as Director of Engineering at Juniper Networks from May 1999 to June 2000 and served as its Vice President of Hardware Engineering from June 2000 to January 2002 and Vice President of Engineering from January 2002 to September 2003. Mr. Krishnamurthi held engineering and management positions at Sun Microsystems, Philips, Xerox PARC, and AT&T Bell Labs. He served as Vice Chairman of Xsigo Systems, Inc. He currently is a general partner at GreatPoint venture. Ashok is also an early investor in a number of companies like GoEuro, Reflektion, OttoQ, Veradocs, Falcon Systems, Robin Systems, and Scoredata amongst others. He is currently on the board of K2 Cyber Security, COSY, Namogoo, OttoQ, InsightRX, Scoredata and the non-profit ALCMI.He holds a BS from the Manipal Institute of Technology and a Master’s degree in Computer Engineering from Syracuse University.
- Total investments:
- 20
- Last investment:
- Lead investor:
- 50%
Last updated:
For AI agents: llms.txt
Industries Ashok Krishnamurthi invests in
Stages Ashok Krishnamurthi invests in
Countries Ashok Krishnamurthi invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Software 4 (20%)
- Health Care 4 (20%)
- Biotechnology 3 (15%)
- Medical Device 2 (10%)
- Artificial Intelligence 2 (10%)
Stage
- Series A 7 (35%)
- Series B 5 (25%)
- Series C 3 (15%)
- Seed 2 (10%)
- Funding Round 2 (10%)
Country
- United States 9 (45%)
- Israel 1 (5%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Recogni was incorporated in 2017 to help auto manufacturers reach Level 2+ vehicle autonomy, but their roots go way back to 2013. The company's platform delivers unprecedented inference performance and power efficiency, enabling clients to get novel edge processing | $102M / Series C / Feb 20, 2024 | ||
| Linus Biotechnology develops a technology platform that builds on breakthroughs in exposome sequencing. The company was founded in 2020 by Manish Arora and is headquartered in New York, United States. | $16M / Series A / Jan 06, 2023 | ||
| Onymos is an information technology company that offers a mobile foundation that bundles end-to-end functions and building blocks to create software applications. The company specializes in the fields of software development, mobile apps, and information technology. | $12M / Series A / Jun 14, 2022 | ||
| Nowsta is an all-in-one software for hourly and event-based workforces, providing scheduling, time tracking, and fintech solutions. It helps employers become better managers by giving them the tools they need to seamlessly manage their hourly workforce. The company is building a platform that leverages advancements in machine learning and paymentstechnology to reimagine the way companies communicate with, and pay their hourly wage employees.Nowsta was established in 2015 and is headquartered in Brooklyn, New York, United States.Nowsta | $41M / Series B / Jan 19, 2022 | ||
| KlearNow is a customs clearance and document management platform built for today’s importers, brokers and transporters. By combining AI technology with a cloud-based platform, partners can now do more business, at a lower cost with full transparency from any smart device 24 hours a day. KlearNow offers a way to clear customs, track shipments, andaccess critical data in real-time. | $50M / Series B / Dec 13, 2021 | ||
| Activ Surgical is a digital surgery company focused on improving surgical efficiency, accuracy, patient outcomes, and accessibility. Its scalable and patent-protected surgical software platform technology is driven by computer vision, artificial intelligence, analytics, and machine learning to enhance a surgeon’s intra-operative decision making,and reduce unintended and preventable surgical complications.The company was founded in 2017 and is headquartered in Boston, Massachusetts. | $45M / Series B / Jul 02, 2021 | ||
| AI processor inspired by the brain's ability to process only relevant data | $6.6M / Seed / Feb 25, 2021 | ||
| Truvian disrupts the blood-testing industry by developing an automated, benchtop diagnostic system to provide lab-accurate results.The blood-testing system combines chemistry, immunoassays, and hematology assays in one device. With its 20-minute, single-run wellness panel that requires only several drops of blood, the company aims to cover about40 commonly ordered diagnostic tests, including a lipid panel, metabolic panel, and complete blood cell count. Its dry reagent and optical sensing technologies, which require no refrigeration, can perform a complete blood count, basic metabolic and lipid panel, hemoglobin and glucose tests, thyroid screenings, and liver and kidney function exams. The company also offers Easy Check, a blood-based serologic test Truvian claims can detect the presence of the antibodies effective against SARS-CoV-2, the virus that causes COVID-19.Dena Marrinucci, Kim Kamdar, Mark Bowles, and Pieter van Rooyen established the San Diego, California-based company in 2015. | $105M / Series C / Feb 24, 2021 | ||
| Recogni was incorporated in 2017 to help auto manufacturers reach Level 2+ vehicle autonomy, but their roots go way back to 2013. The company's platform delivers unprecedented inference performance and power efficiency, enabling clients to get novel edge processing | $48.9M / Series B / Feb 17, 2021 | ||
| Excision BioTherapeutics is a private company focused on developing advanced gene-editing therapeutics to address the medical need for the treatment of life-threatening diseases caused by viral infections. They develop gene-editing medicines that eradicate or disrupt viral genes in human patients. Their mission is to advance gene-editingtherapeutics for our indications into safe and efficacious medicines that will greatly improve the lives of infected individuals around the world. | $60M / Feb 17, 2021 | ||
| See all 20 investments → | |||
Co-Investors
About GreatPoint Ventures
GreatPoint Ventures is an early-stage venture capital firm investing between $250k and $20m into Seed, A, and B rounds. The firm was founded in San Francisco, California in 2015.
GreatPoint Ventures Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Aaron Mandell
Founder
|
|||
Andrew Perlman
Founder & Managing Partner
|
|||
|
Ashley Sommerschield
Chief Operating Officer
|
|||
|
Ashok Krishnamurthi
Managing Partner
|
|||
Earnest Sweat
Associate Partner
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Ashok Krishnamurthi invest in?
Ashok Krishnamurthi invests primarily in Software, Health Care and Biotechnology startups, most often at Series A and Series B stage. Most of the 20 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Ashok Krishnamurthi?
Public channels for Ashok Krishnamurthi include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Ashok Krishnamurthi last invest?
The most recent investment recorded for Ashok Krishnamurthi closed in Feb 2024. Shizune tracks 20 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
